Candidemia in Colombia: Species Distribution and Antifungal Susceptibility Profiles of Yeast Bloodstream Isolates from a Six-Year Multicentre Surveillance Study
Authors:
- Andres Ceballos-GarzonAndres Ceballos-Garzon
- Nicolas BeltranNBNicolas Beltran
- Valeri SaenzVSValeri Saenz
- Luz-Angela PescadorLPLuz-Angela Pescador
- Diego JosaDJDiego Josa
- Alejandro Rodriguez-BobadillaARAlejandro Rodriguez-Bobadilla
- Luisa-Fernanda RodriguezLRLuisa-Fernanda Rodriguez
- Rosalba Quintero-MunozRQRosalba Quintero-Munoz
- Ivan-Felipe GutierrezIGIvan-Felipe Gutierrez
- Maria del Pilar Torres-NavarreteMTMaria del Pilar Torres-Navarrete
- Liliana ArevaloLALiliana Arevalo
- Diana P. Cely-LadinoDCDiana P. Cely-Ladino
Open Access
- 27 August 2026
- journal article
- research article
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (9) , 640
Abstract
A multicentre, laboratory-based analysis was conducted on aggregated data from 23 hospitals across Colombia. Of 1761 fungal isolates identified, 1642 were yeasts and constitute the focus of this study. Isolates were identified using the VITEK®2 system, with confirmatory identification by MALDI-TOF-MS for a subset. Antifungal susceptibility testing for fluconazole, voriconazole, amphotericin B, and the echinocandins was performed on Candida albicans, C. parapsilosis, and C. tropicalis. Data were stratified by clinical service: adult ICU, adult wards, paediatric ICU, neonatal ICU, and paediatric wards. Temporal trends were assessed using the Cochran–Armitage test. The most prevalent species were C. albicans (42%), C. parapsilosis (24%), C. tropicalis (11%), C. glabrata (7%), and C. auris (3%). C. albicans predominated in adult services, whereas C. parapsilosis was the leading pathogen across paediatric settings. Among species with validated breakpoints, the overall fluconazole resistance rate was 19%, driven primarily by C. parapsilosis (35%, exceeding 40% in some clinical services). Non-wild-type to voriconazole and amphotericin B was low (C. parapsilosis, together with the emergence of C. auris, underscores the urgent need for sustained surveillance and species-directed antifungal stewardship programmes.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Fungal diagnostics and antifungal drug access in Latin America and the Caribbean: an ESCMID EFISG multinational surveyNature Communications, 2026
- Diagnostic and therapeutic capacity for fungal infections in Colombia: An ESCMID-EFISG nationwide multicenter assessment of mycological healthcareInternational Journal of Infectious Diseases, 2025
- Global incidence and mortality of severe fungal diseaseThe Lancet Infectious Diseases, 2024
- Candidemia in Brazilian neonatal intensive care units: risk factors, epidemiology, and antifungal resistanceBrazilian Journal of Microbiology, 2023
- Head‐to‐head comparison of CLSI, EUCAST, Etest and VITEK®2 results for Candida auris susceptibility testingInternational Journal of Antimicrobial Agents, 2022
- First report of sporadic cases of Candida auris in ColombiaInternational Journal of Infectious Diseases, 2018
- Comparison of the VITEK 2 antifungal susceptibility system with Etest using clinical isolates of Candida speciesRevista Iberoamericana de Micologia, 2017
- Epidemiology of Candida isolates from Intensive Care Units in Colombia from 2010 to 2013Revista Iberoamericana de Micologia, 2017
- Association of clinical and demographic factors in invasive candidiasis caused by fluconazole-resistant Candida species: a study in 15 hospitals, Medellín, Colombia 2010–2011Diagnostic Microbiology and Infectious Disease, 2014
- Fungal bloodstream infections in tertiary care hospitals in ColombiaRevista Iberoamericana de Micologia, 2011